At July 31, 2026, and April 30, 2026, the Company had one reportable segment, being antibody discovery and related services.

The Company’s revenues are allocated to geographic regions for the three months ended July 31, 2026, and 2025 as follows:


	Three months ended July 31,
(in thousands)	2026 $		2025 $
United States of America		2,554		2,449
Europe		174		520
Canada		120		174
Australia		—		18
Other		986		—
		3,834		3,161

The Company’s revenues are allocated according to revenue types for the three months ended July 31, 2026, and 2025 as follows:


	Three months ended July 31,
(in thousands)	2026 $		2025 $
Project revenue		3,831		3,126
Product sales revenue		1		2
Cryostorage revenue		2		33
		3,834		3,161

The Company’s non-current assets are allocated to geographic regions as of July 31, 2026, and April 30, 2026 as follows:


	July 31, 2026 $		April 30, 2026 $
North America - Corporate		89		82
North America		4,711		4,741
Belgium		309		333
Netherlands		—		—
		5,109		5,156

Geographic segmentation of the Company’s net income (loss) for the three months ended July 31, 2026, and 2025 is as follows:


	Three months ended July 31,
(in thousands)	2026 $			2025 $
North America - Corporate		(268	)		(2,810	)
North America		376			307
Belgium		(3,223	)		(1,781	)
Netherlands		(2,970	)		1,325
		(6,085	)		(2,959	)

Geographic segmentation of the interest and accretion, and amortization and depreciation for the three months ended July 31, 2026, and 2025 is as follows:


	Three months ended July 31,
Interest and accretion (in thousands)	2026 $		2025 $
North America - Corporate		—		—
North America		55		59
Belgium		—		—
Netherlands		—		—
		55		59


	Three months ended July 31,
Amortization and depreciation (in thousands)	2026 $		2025 $
North America - Corporate		—		1
North America		172		181
Belgium		91		19
Netherlands		3		—
		266		201